The incidence of Chlamydia pneumoniae infection was determined in patients with chronic obstructive pulmonary diseases (COPD) by prospective serial serology. Chlamydia-specific IgG, IgM and IgA antibodies were detected with a recombinant DNA lipopolysaccharide (LPS) ELISA as well as with a micro-immunofluorescence (MIF) assay with C. pneumoniae elementary bodies. From 271. consecutive COPD patients who visited the outpatient clinic of the department of pulmonary diseases (211 males, 60 females, age 'range 34-88 years, mean age 66 SD 10 years), blood samples (n = 1058) were taken every 2-7 months; the observation period ranged from 3 to 19 months (mean 15 SD 4). The prevalence of chlamydial IgG was 72% with the MIF and 53% with the rDNA LPS ELISA. More than 90% of the COPD patients had no significant changes in their chlamydia-specific IgG, IgA and IgM titres in either test during the observation period. Seven (3%) patients had MIF results indicating acute C. pneumoniae infection during their surveillance period, of whom five were confirmed by rDNA LPS ELISA. Eleven (4%) additional patients were infected during observation, as determined by rDNA LPS ELISA only. These patients had significantly elevated C.
Introduction
Infection with Chlamydia pneumoniae occurs worldwide, resulting in a 40-90% prevalence of serum antibody to the species in various populations [ 1-41. C. pneumoniae has been associated with both epidemic and endemic occurrences of acute respiratory disease and is believed to be responsible for 6-20% of all community-acquired pneumonias [ 5 -lo] . However, the role of C. pneumoniae in the pathogenesis of recurrent exacerbations of chronic obstructive pulmonary diseases (COPD) is unknown. Serology is currently the tool used most often for routine diagnosis of recent C. pneumoniae infection. The standard serological technique at this moment is the micro-immunofluorescence (MIF) test. Chlamydia elementary bodies (EBs), which are the infective cell forms of chlamydia, are used as antigen in the MIF test. This test is claimed to be species-specific and can differentiate between IgG, IgM and IgA antibodies [ 11, 121. This study evaluated a commercial rDNA lipopolysaccharide (LPS) ELISA (Medac GmbH, Hamburg,
Patients and methods

Patients
The study population consisted of 271 patients (21 1 males and 60 females) with COPD attending the outpatient clinic of the pulmonary disease unit at the St Antonius Hospital, Nieuwegein, The Netherlands. The age range of the patients was 34-88 years with a median of 67 years. Blood samples were taken from each patient every 2-7 months (median 4 months). The surveillance period ranged from 3 to 19 months (median 15 months). All serum samples from each patient were tested in one run to prevent misinterpretation due to day-to-day variation in the assays.
Serology
The micro-immunofluorescence assay (MIF) was used to measure specific IgG, IgM and IgA antibodies to C. pneumoniae (Cp) elementary bodies (Washington Research Foundation, Seattle, WA, USA) [ll] . In addition, a commercially available MIF test (Labsystems OY, Finland) was used to distinguish between C. pneumoniae, C. trachomatis and C. psittaci LPSspecific antibodies. The prevalence of Cp-specific IgG, IgM and IgA antibodies was based on the presence of antibodies at titres 3 32, 2 16 and a 32, respectively. Diagnosis of a Cp infection during surveillance was based on the presence of Cp-specific IgM in any serum sample, or a four-fold or greater titre increase in Cp-specific IgG or IgA antibody, or both, between two consecutive serum samples [ 113. All twofold dilutions were made by a pipetting robot (MARK 5 ; DPC, Los Angeles, CA, USA).
Chlamydia-specific IgG, IgM and IgA antibodies were also detected by a recombinant DNA (rDNA) LPS ELISA (Medac GmbH, Hamburg, Germany). This ELISA is based on a chemically pure, recombinant .LPS which contains a genus-specific epitope of Chlamydia spp. [13-151. Each serum sample was mixed thoroughly before processing according to the manufacturer's instructions. Initial serum dilutions for IgG, IgM and IgA antibody measurements were 1 in 100, 1 in 50 and 1 in 50, respectively. Sera with OD values >2.5 were re-tested at a pre-dilution of 1 in 4. A two-fold serially diluted standard serum was used to calculate the log2 titre of the patients' samples. The IgG, IgM and IgA cut-off values were calculated as prescribed by the manufacturer. The prevalence of chlamydia-specific IgG, IgM and IgA antibodies was based on the following criteria:
calculated cut-off X 1.10, 3 calculated cut-off X 1.15 and 3 calculated cut-off X 1.10, respectively. Serological diagnosis of an acute chlamydia infection was based on the ELISA results with the following criteria: a three-fold or greater increase in chlamydia-specific IgG or IgA antibody titre, or a two-fold increase in specific IgM titre, or a two-fold increase in specific IgG antibody titre in combination with a two-fold increase in specific IgA antibody titre. All pipetting was done by the same pipetting robot.
Results
The intra-assay variability of the chlamydia IgG, IgM and IgA rDNA LPS ELISA was calculated by testing a positive serum sample 10 times in one run. The interassay variability was calculated by testing a positive sample in 10 different runs. A standard curve was used to calculate the titre of the patient sample. The intraand inter-assay variabilities ranged from 2.8 to 6.7% and from 10.6 to 12.2%, respectively.
A total of 1058 serum samples from 271 COPD patients was tested in this study. The C. pneumoniae IgG seroprevalence observed by MIF was 72% when the first serum sample from each patient was tested. A seroprevalence of 53% was found when the chlamydia IgG rDNA LPS ELISA was applied to the same sera. Corresponding results for IgG with both tests were found in ,182 (67%) of the COPD patients; 70 (79%) of 89 patients with discordant IgG results were MIF positive and rDNA LPS ELISA negative. There was very little discordance in IgM results; 9 (90%) of 10 patients with discordant IgM results were rDNA positive and MIF negative. Eighty-nine (33%) of the 271 sera showed discordant IgA results; again, 52 (58%) of 89 patients had positive MIF results with negative rDNA LPS ELISA results (Table 1) .
No significant changes in chlamydia-specific IgG, IgM and IgA antibody during the surveillance period were found in 263 (97%) and 248 (92%) patients, as observed by MIF and rDNA LPS ELISA, respectively. The antibody titres of these individuals were constant over time with very limited shifts observed between consecutive samples (Fig. 1 ).
Seven (3%) patients had MIF results indicating C. pneumoniae infection during their surveillance period. These results were confirmed in five of the patients by rDNA LPS ELISA. Eleven more patients were Table 2 ). The serological profiles of all 18 patients with evidence of infection during their surveillance period are presented in Table 3 . All 18 patients were also tested with the commercially available MIF test from Labsystems. This MIF assay uses three . different antigen spots/well, to distinguish between C. pneumoniae, C. trachomatis and C.
psittaci LPS-specific antibodies. None of the patients yielded serological results indicating recent C. trachomatis or C. psittaci infection. In addition, no significant differences in the C. pneumoniae titres for these patients were found, as compared with the 'in-house' MIF (data not shown).
Two patients had chlamydia IgM rDNA LPS ELISA results indicative of C. pneumoniae infection at entry to the study. Three patients had positive chlamydia IgM rDNA LPS ELISA results during their entire surveillance period (observation period ranged from 13 to 18 months). In two of these patients, no significant titre change in IgM reactivity was observed over time.
One patient had a significant IgM titre fall between the first and the last serum sample. None of these patients had MIF IgM reactivity. Four other patients had chlamydia IgM rDNA LPS ELISA results close to the cut-off value during their entire surveillance period. Again, none of these patients had MIF IgM reactivity. 
Discussion
Serology is the most commonly used diagnostic tool for the detection of respiratory chlamydial infections in routine clinical practice. In the early 1970s, a sensitive micro-immunofluorescence (MIF) assay was developed which proved to be suitable for routine diagnosis [16, 171. In the MIF test, purified elementary bodies are used to detect specific chlamydia antibodies in the IgM, IgG and IgA serum fractions. The MIF test is generally accepted as the gold standard for the serological diagnosis of an acute C. pneumoniae infection. However, interpretation of specific and non-specific fluorescence patterns requires experience and skill, and the interpretation of high titres (2 512) is very difficult and subjective. In addition, cross-reactions between C.
pneumoniae and other chlamydial species have been reported [18] [19] [20] . Chemically pure antigens have been isolated for the detection of antibodies against chlamydial LPS and this has been developed into a commercially available recombinant DNA LPS ELISA [13-151. In the present study, this rDNA LPS ELISA developed for the detection of chlamydia-specific IgG, IgM and IgA antibodies achieved a high degree of reproducibility, Partial concordance in seroprevalence was found with the in-house C. pneumoniae MIF assay. There were discordant results between the two tests however, and a lower seroprevalence was found with the rDNA LPS ELISA as compared with the in-house MIF. One possible explanation for this is that anti-LPS chlamydial antibodies may have a shorter half-life than the MOMP antibodies detected by MIF. However, the serological data obtained-by MIF and the rDNA LPS ELISA were identical in > 95% of the patients. On the other hand, the rDNA LPS ELISA seems to be more sensitive for the detection of acute respiratory chlamydial infection than the traditional MIF. The major issue of this study is the validity of the tests used, especially the new rDNA LPS ELISA. However, the major problem in validating a new test is the definition of a gold standard. Culture or PCR, or both, may be used to calculate the sensitivity and specificity of serological assays. However, asymptomatic infection, often without a serological response, has been reported [23-261 and little is known about the role of the organism as a commensal and the possibility of c d e r status. Most clinicians are interested in diagnosing acute C. pneumoniae infections and a significant increase of chlamydia-specific antibodies between acute and convalescent serum samples is generally considered to be an indication of acute infection. The incidence found in this COPD patient group by MIF was comparable with the incidence found by Grayston [27]. An increased incidence was found when the rDNA LPS ELISA was used.
In conclusion, the study shows that the rDNA LPS chlamydia assay may currently be the most sensitive serological method for the diagnosis of recent respiratory infection with Chlamydia spp. C. pneumoniae infection may make a significant contribution to morbidity in COPD patients.
